DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic knee osteoarthritis), NCT06097663 (coronary...
- Mechanism
- Curator reviewed
DFV890 (previously known as IFM-2427) is a systemic NLRP3 antagonist: by blocking NLRP3 effects, IFM-2427 reduces inflammatory signalling and the assembly of multi-protein complexes that result from maturation of cytokines like IL-1, IL-18 and necrosis. This dampening of the NLRP3-initiated immune response allows other immune pathways to produce inflammatory responses to handle harmful pathogens and reduces the often negative downstream effects that occur as a result of NLRP3 activation. Novartis took over DFV890 when it purchased the biotech firm, IFM Tre. The compound is currently being tested in Phase 2 human clinical triasl for safety and efficacy in patients with COVID-19.
- Code names
- DFV890 · IFM-2427
Resolves to
What you can answer from here — as of July 08, 2026
Which drugs share a target with DFV890, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account